دورية أكاديمية
أعرض في EDS

Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.

التفاصيل البيبلوغرافية
العنوان: Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
المؤلفون: Roldan-Romero, Juan María, Santos, María, Lanillos, Javier, Caleiras, Eduardo, Anguera, Georgia, Maroto, Pablo, García-Donas, Jesús, de Velasco, Guillermo, Martinez-Montes, Ángel Mario, Calsina, Bruna, Monteagudo, María, Letón, Rocío, Leandro-García, Luis Javier, Montero-Conde, Cristina, Cascón, Alberto, Robledo Batanero, Mercedes, Rodriguez Antona, Cristina
المساهمون: Ministerio de Economía, Industria y Competitividad (España), Fundación La Caixa, Fundación Rafael del Pino, Asociación Española Contra el Cáncer, Fundación Banco Santander, Agencia Estatal de Investigación (España), Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Ministerio de Educación, Cultura y Deporte (España), Spanish Oncology Genitourinary Group (SOGUG)
بيانات النشر: Elsevier
سنة النشر: 2020
المجموعة: REPISALUD (REPositorio Institucional en SALUD del Instituto de Salud Carlos III - ISCIII)
مصطلحات موضوعية: Mutation, Adult, Aged, 80 and over, Biomarkers, Tumor, Carcinoma, Renal Cell, DNA Mutational Analysis, Female, Genetic Predisposition to Disease, High-Throughput Nucleotide Sequencing, Humans, Immunohistochemistry, Kidney Neoplasms, Male, Middle Aged, PTEN Phosphohydrolase, Phenotype, Phosphorylation, Ribosomal Protein S6 Kinases, TOR Serine-Threonine Kinases, Tuberous Sclerosis Complex 1 Protein, Tuberous Sclerosis Complex 2 Protein, Tumor Suppressor Protein p53
الوصف: Chromophobe renal cell carcinoma (chRCC) is a histologically and molecularly distinct class of rare renal tumor. TCGA studies revealed low mutational burden, with only TP53 and PTEN recurrently mutated, and discovered alterations in TERT promoter and in the electron transport chain Complex I genes. However, knowledge on drug targetable genes is limited and treatments at metastatic stage do not follow a molecular rationale. In a large series of 92 chRCC enriched with metastatic cases, we performed an in-depth characterization of mTOR pathway alterations through targeted NGS and immunohistochemistry (IHC) of phospho-S6, tuberin, and PTEN. Mutations in mitochondria, telomere maintenance and other renal cancer related genes and p53 IHC, were also assessed. The impact on metastasis development and disease specific survival was determined, using TCGA-KICH series (n = 65) for validation. mTOR pathway mutations (MTOR, TSC1, TSC2) were present in 17% of primary tumors, most of them being classified as pathogenic. Mutations were associated with positive IHC staining of phospho-S6 and PTEN (P = 0.009 and P = 0.001, respectively) and with chRCC eosinophilic variant (P = 0.039), supporting a biological relevance of the pathway. mTOR pathway mutations were associated with worse clinical outcomes. Survival analysis gave a hazard ratio of 5.5 (P = 0.027), and this association was confirmed in TCGA-KICH (HR = 10.3, P = 0.006). TP53 mutations were enriched in metastatic cases (P = 0.018), and mutations in telomere maintenance genes showed a trend in the same direction. p53 IHC staining pattern was associated with the underlying TP53 defect, and negative PTEN IHC staining (82% of cases) suggested PTEN loss as a chRCC hallmark. In conclusion, our study provides with novel genomic knowledge in chRCC and identifies novel markers of poor survival. Furthermore, this is the first study showing that mTOR pathway mutations correlate with poor prognosis, and may help to identify patients with increased sensitivity to mTOR inhibitors. ...
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 1530-0285
العلاقة: https://doi.org/10.1038/s41379-020-0607-zTest.; Mod Pathol . 2020;33(12):2580-2590; http://hdl.handle.net/20.500.12105/17510Test; Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
DOI: 10.1038/s41379-020-0607-z
الإتاحة: https://doi.org/20.500.12105/17510Test
https://doi.org/10.1038/s41379-020-0607-zTest
https://hdl.handle.net/20.500.12105/17510Test
حقوق: http://creativecommons.org/licenses/by-nc-nd/4.0Test/ ; Attribution-NonCommercial-NoDerivatives 4.0 Internacional ; open access
رقم الانضمام: edsbas.872004FA
قاعدة البيانات: BASE
ResultId 1
Header edsbas
BASE
edsbas.872004FA
918
3
Academic Journal
academicJournal
917.616333007813
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.872004FA&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://doi.org/20.500.12105/17510# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsbas&genre=article&issn=15300285&ISBN=&volume=&issue=&date=20200101&spage=&pages=&title=Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.&atitle=Molecular%20characterization%20of%20chromophobe%20renal%20cell%20carcinoma%20reveals%20mTOR%20pathway%20alterations%20in%20patients%20with%20poor%20outcome.&id=DOI:10.1038/s41379-020-0607-z [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Roldan-Romero%2C+Juan+María%22">Roldan-Romero, Juan María</searchLink><br /><searchLink fieldCode="AR" term="%22Santos%2C+María%22">Santos, María</searchLink><br /><searchLink fieldCode="AR" term="%22Lanillos%2C+Javier%22">Lanillos, Javier</searchLink><br /><searchLink fieldCode="AR" term="%22Caleiras%2C+Eduardo%22">Caleiras, Eduardo</searchLink><br /><searchLink fieldCode="AR" term="%22Anguera%2C+Georgia%22">Anguera, Georgia</searchLink><br /><searchLink fieldCode="AR" term="%22Maroto%2C+Pablo%22">Maroto, Pablo</searchLink><br /><searchLink fieldCode="AR" term="%22García-Donas%2C+Jesús%22">García-Donas, Jesús</searchLink><br /><searchLink fieldCode="AR" term="%22de+Velasco%2C+Guillermo%22">de Velasco, Guillermo</searchLink><br /><searchLink fieldCode="AR" term="%22Martinez-Montes%2C+Ángel+Mario%22">Martinez-Montes, Ángel Mario</searchLink><br /><searchLink fieldCode="AR" term="%22Calsina%2C+Bruna%22">Calsina, Bruna</searchLink><br /><searchLink fieldCode="AR" term="%22Monteagudo%2C+María%22">Monteagudo, María</searchLink><br /><searchLink fieldCode="AR" term="%22Letón%2C+Rocío%22">Letón, Rocío</searchLink><br /><searchLink fieldCode="AR" term="%22Leandro-García%2C+Luis+Javier%22">Leandro-García, Luis Javier</searchLink><br /><searchLink fieldCode="AR" term="%22Montero-Conde%2C+Cristina%22">Montero-Conde, Cristina</searchLink><br /><searchLink fieldCode="AR" term="%22Cascón%2C+Alberto%22">Cascón, Alberto</searchLink><br /><searchLink fieldCode="AR" term="%22Robledo+Batanero%2C+Mercedes%22">Robledo Batanero, Mercedes</searchLink><br /><searchLink fieldCode="AR" term="%22Rodriguez+Antona%2C+Cristina%22">Rodriguez Antona, Cristina</searchLink> )
Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => Ministerio de Economía, Industria y Competitividad (España)<br />Fundación La Caixa<br />Fundación Rafael del Pino<br />Asociación Española Contra el Cáncer<br />Fundación Banco Santander<br />Agencia Estatal de Investigación (España)<br />Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)<br />Ministerio de Educación, Cultura y Deporte (España)<br />Spanish Oncology Genitourinary Group (SOGUG) )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Elsevier )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2020 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => REPISALUD (REPositorio Institucional en SALUD del Instituto de Salud Carlos III - ISCIII) )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Mutation%22">Mutation</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%22">Aged</searchLink><br /><searchLink fieldCode="DE" term="%2280+and+over%22">80 and over</searchLink><br /><searchLink fieldCode="DE" term="%22Biomarkers%22">Biomarkers</searchLink><br /><searchLink fieldCode="DE" term="%22Tumor%22">Tumor</searchLink><br /><searchLink fieldCode="DE" term="%22Carcinoma%22">Carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22Renal+Cell%22">Renal Cell</searchLink><br /><searchLink fieldCode="DE" term="%22DNA+Mutational+Analysis%22">DNA Mutational Analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Genetic+Predisposition+to+Disease%22">Genetic Predisposition to Disease</searchLink><br /><searchLink fieldCode="DE" term="%22High-Throughput+Nucleotide+Sequencing%22">High-Throughput Nucleotide Sequencing</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Immunohistochemistry%22">Immunohistochemistry</searchLink><br /><searchLink fieldCode="DE" term="%22Kidney+Neoplasms%22">Kidney Neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22PTEN+Phosphohydrolase%22">PTEN Phosphohydrolase</searchLink><br /><searchLink fieldCode="DE" term="%22Phenotype%22">Phenotype</searchLink><br /><searchLink fieldCode="DE" term="%22Phosphorylation%22">Phosphorylation</searchLink><br /><searchLink fieldCode="DE" term="%22Ribosomal+Protein+S6+Kinases%22">Ribosomal Protein S6 Kinases</searchLink><br /><searchLink fieldCode="DE" term="%22TOR+Serine-Threonine+Kinases%22">TOR Serine-Threonine Kinases</searchLink><br /><searchLink fieldCode="DE" term="%22Tuberous+Sclerosis+Complex+1+Protein%22">Tuberous Sclerosis Complex 1 Protein</searchLink><br /><searchLink fieldCode="DE" term="%22Tuberous+Sclerosis+Complex+2+Protein%22">Tuberous Sclerosis Complex 2 Protein</searchLink><br /><searchLink fieldCode="DE" term="%22Tumor+Suppressor+Protein+p53%22">Tumor Suppressor Protein p53</searchLink> )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Chromophobe renal cell carcinoma (chRCC) is a histologically and molecularly distinct class of rare renal tumor. TCGA studies revealed low mutational burden, with only TP53 and PTEN recurrently mutated, and discovered alterations in TERT promoter and in the electron transport chain Complex I genes. However, knowledge on drug targetable genes is limited and treatments at metastatic stage do not follow a molecular rationale. In a large series of 92 chRCC enriched with metastatic cases, we performed an in-depth characterization of mTOR pathway alterations through targeted NGS and immunohistochemistry (IHC) of phospho-S6, tuberin, and PTEN. Mutations in mitochondria, telomere maintenance and other renal cancer related genes and p53 IHC, were also assessed. The impact on metastasis development and disease specific survival was determined, using TCGA-KICH series (n = 65) for validation. mTOR pathway mutations (MTOR, TSC1, TSC2) were present in 17% of primary tumors, most of them being classified as pathogenic. Mutations were associated with positive IHC staining of phospho-S6 and PTEN (P = 0.009 and P = 0.001, respectively) and with chRCC eosinophilic variant (P = 0.039), supporting a biological relevance of the pathway. mTOR pathway mutations were associated with worse clinical outcomes. Survival analysis gave a hazard ratio of 5.5 (P = 0.027), and this association was confirmed in TCGA-KICH (HR = 10.3, P = 0.006). TP53 mutations were enriched in metastatic cases (P = 0.018), and mutations in telomere maintenance genes showed a trend in the same direction. p53 IHC staining pattern was associated with the underlying TP53 defect, and negative PTEN IHC staining (82% of cases) suggested PTEN loss as a chRCC hallmark. In conclusion, our study provides with novel genomic knowledge in chRCC and identifies novel markers of poor survival. Furthermore, this is the first study showing that mTOR pathway mutations correlate with poor prognosis, and may help to identify patients with increased sensitivity to mTOR inhibitors. ... )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1530-0285 )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://doi.org/10.1038/s41379-020-0607-z.; Mod Pathol . 2020;33(12):2580-2590; http://hdl.handle.net/20.500.12105/17510; Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1038/s41379-020-0607-z )
Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/20.500.12105/17510<br />https://doi.org/10.1038/s41379-020-0607-z<br />https://hdl.handle.net/20.500.12105/17510 )
Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => http://creativecommons.org/licenses/by-nc-nd/4.0/ ; Attribution-NonCommercial-NoDerivatives 4.0 Internacional ; open access )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.872004FA )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1038/s41379-020-0607-z ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Mutation [Type] => general ) [1] => Array ( [SubjectFull] => Adult [Type] => general ) [2] => Array ( [SubjectFull] => Aged [Type] => general ) [3] => Array ( [SubjectFull] => 80 and over [Type] => general ) [4] => Array ( [SubjectFull] => Biomarkers [Type] => general ) [5] => Array ( [SubjectFull] => Tumor [Type] => general ) [6] => Array ( [SubjectFull] => Carcinoma [Type] => general ) [7] => Array ( [SubjectFull] => Renal Cell [Type] => general ) [8] => Array ( [SubjectFull] => DNA Mutational Analysis [Type] => general ) [9] => Array ( [SubjectFull] => Female [Type] => general ) [10] => Array ( [SubjectFull] => Genetic Predisposition to Disease [Type] => general ) [11] => Array ( [SubjectFull] => High-Throughput Nucleotide Sequencing [Type] => general ) [12] => Array ( [SubjectFull] => Humans [Type] => general ) [13] => Array ( [SubjectFull] => Immunohistochemistry [Type] => general ) [14] => Array ( [SubjectFull] => Kidney Neoplasms [Type] => general ) [15] => Array ( [SubjectFull] => Male [Type] => general ) [16] => Array ( [SubjectFull] => Middle Aged [Type] => general ) [17] => Array ( [SubjectFull] => PTEN Phosphohydrolase [Type] => general ) [18] => Array ( [SubjectFull] => Phenotype [Type] => general ) [19] => Array ( [SubjectFull] => Phosphorylation [Type] => general ) [20] => Array ( [SubjectFull] => Ribosomal Protein S6 Kinases [Type] => general ) [21] => Array ( [SubjectFull] => TOR Serine-Threonine Kinases [Type] => general ) [22] => Array ( [SubjectFull] => Tuberous Sclerosis Complex 1 Protein [Type] => general ) [23] => Array ( [SubjectFull] => Tuberous Sclerosis Complex 2 Protein [Type] => general ) [24] => Array ( [SubjectFull] => Tumor Suppressor Protein p53 [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Roldan-Romero, Juan María ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Santos, María ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Lanillos, Javier ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Caleiras, Eduardo ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Anguera, Georgia ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Maroto, Pablo ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => García-Donas, Jesús ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => de Velasco, Guillermo ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Martinez-Montes, Ángel Mario ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Calsina, Bruna ) ) ) [10] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Monteagudo, María ) ) ) [11] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Letón, Rocío ) ) ) [12] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Leandro-García, Luis Javier ) ) ) [13] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Montero-Conde, Cristina ) ) ) [14] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Cascón, Alberto ) ) ) [15] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Robledo Batanero, Mercedes ) ) ) [16] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Rodriguez Antona, Cristina ) ) ) [17] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Ministerio de Economía, Industria y Competitividad (España) ) ) ) [18] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Fundación La Caixa ) ) ) [19] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Fundación Rafael del Pino ) ) ) [20] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Asociación Española Contra el Cáncer ) ) ) [21] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Fundación Banco Santander ) ) ) [22] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Agencia Estatal de Investigación (España) ) ) ) [23] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) ) ) ) [24] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Ministerio de Educación, Cultura y Deporte (España) ) ) ) [25] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Spanish Oncology Genitourinary Group (SOGUG) ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2020 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 15300285 ) [1] => Array ( [Type] => issn-locals [Value] => edsbas ) [2] => Array ( [Type] => issn-locals [Value] => edsbas.oa ) ) ) ) ) ) )
IllustrationInfo